Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has announced that the FDA has approved Advair Diskus 250/50 for the reduction of exacerbations in patients with chronic obstructive pulmonary disease who have a history of exacerbations.
Subscribe to our email newsletter
The FDA also expanded the use of Advair Diskus 250/50 to a broader patient population which includes not only patients with chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis, but also emphysema or both conditions.
According to the company, Advair 250/50 is the only approved strength for COPD in the US, because an efficacy advantage of the higher strength over Advair 250/50 has not been demonstrated.
Advair contains two medicines, an inhaled corticosteroid (fluticasone propionate) and a long-acting beta-agonist (salmeterol), that work together to improve lung function and reduce exacerbations, two primary goals in the management of COPD.